Commonwealth of Pennsylvania Public School Empls Retrmt SYS Takes $522,000 Position in Amneal Pharmaceuticals, Inc. $AMRX

Commonwealth of Pennsylvania Public School Empls Retrmt SYS bought a new position in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) in the 1st quarter, HoldingsChannel reports. The fund bought 41,980 shares of the company’s stock, valued at approximately $522,000.

Other institutional investors and hedge funds have also modified their holdings of the company. Oliver Luxxe Assets LLC purchased a new stake in Amneal Pharmaceuticals in the 4th quarter worth about $1,972,000. Artemis Investment Management LLP acquired a new stake in Amneal Pharmaceuticals during the 4th quarter worth about $1,574,000. SG Americas Securities LLC grew its stake in Amneal Pharmaceuticals by 2,866.0% during the 4th quarter. SG Americas Securities LLC now owns 784,803 shares of the company’s stock valued at $9,889,000 after acquiring an additional 758,343 shares in the last quarter. Louisiana State Employees Retirement System purchased a new position in Amneal Pharmaceuticals during the 1st quarter valued at about $936,000. Finally, Assenagon Asset Management S.A. increased its holdings in shares of Amneal Pharmaceuticals by 75.0% in the 4th quarter. Assenagon Asset Management S.A. now owns 3,761,739 shares of the company’s stock valued at $47,398,000 after purchasing an additional 1,611,698 shares during the period. Hedge funds and other institutional investors own 31.82% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts recently commented on the stock. UBS Group raised their price target on shares of Amneal Pharmaceuticals from $19.00 to $23.00 and gave the stock a “buy” rating in a report on Wednesday. Zacks Research lowered shares of Amneal Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Monday, April 6th. Wall Street Zen upgraded shares of Amneal Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Sunday, July 12th. Weiss Ratings lowered shares of Amneal Pharmaceuticals from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Tuesday, May 26th. Finally, Barclays boosted their price target on shares of Amneal Pharmaceuticals from $15.00 to $16.00 and gave the company an “overweight” rating in a report on Wednesday, May 20th. Five analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $16.60.

Insider Buying and Selling

In other news, Director Deborah M. Autor sold 34,819 shares of the company’s stock in a transaction that occurred on Monday, May 11th. The stock was sold at an average price of $12.94, for a total transaction of $450,557.86. Following the completion of the transaction, the director directly owned 93,660 shares in the company, valued at $1,211,960.40. The trade was a 27.10% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 17.30% of the stock is currently owned by corporate insiders.

Amneal Pharmaceuticals Stock Performance

Shares of NASDAQ:AMRX opened at $17.85 on Friday. The stock’s 50-day moving average is $15.05 and its 200-day moving average is $13.89. The company has a market cap of $5.69 billion, a P/E ratio of 46.97 and a beta of 1.26. Amneal Pharmaceuticals, Inc. has a 52-week low of $7.66 and a 52-week high of $18.39.

Amneal Pharmaceuticals (NASDAQ:AMRX) last posted its quarterly earnings data on Thursday, May 7th. The company reported $0.27 earnings per share for the quarter. Amneal Pharmaceuticals had a negative return on equity of 313.96% and a net margin of 4.01%.The business had revenue of $722.52 million during the quarter. As a group, equities analysts predict that Amneal Pharmaceuticals, Inc. will post 0.92 EPS for the current year.

About Amneal Pharmaceuticals

Amneal Pharmaceuticals, Inc is a publicly traded integrated healthcare company specializing in the development, manufacturing and distribution of generic and specialty pharmaceutical products. The company’s portfolio includes oral solids, injectables, transdermals and biosimilars, serving a broad range of therapeutic areas such as cardiovascular, neuroscience, oncology and women’s health. Alongside its generic offerings, Amneal has built a branded portfolio through strategic acquisitions and internal development, positioning itself across both high-volume generics and higher-value specialty treatments.

Since its founding in 2002 by brothers Chirag and Chintu Modgil, Amneal has pursued growth through organic investment in research and development as well as targeted M&A.